Medication info
Combiglyze XR 5/500 mg

Combiglyze XR 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletSaxagliptin Hydrate›5.29mg / 1 tablet
Manufacturer / importer
AstraZeneca Korea
Appearance
Pale brown and brown, double convex, film-coated tablet
Packaging
28 tablets (7 tablets × 4)/box
Approval status
Active

MFDS item code 201202805 · Approved 2012.04.12 · Insurance code 650700900

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients who are not currently being treated with metformin and require saxagliptin 5mg, the recommended starting dose of this medicine is one saxagliptin 5mg/metformin 500mg extended-release tablet once daily; adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients being treated with metformin, the recommended dose of saxagliptin is 5mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. - For patients switching from combination therapy with saxagliptin and metformin to this medicine, the dose of this medicine may be started at the doses of saxagliptin and metformin previously administered. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. - Patients who require saxagliptin 2.5mg in combination with extended-release metformin may take this medicine at 2.5mg/1000mg. Patients who require saxagliptin 2.5mg but are not being treated with metformin, or who require more than 1000mg of metformin, should take the individual component formulations. The maximum recommended daily dose is saxagliptin 5mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another antihyperglycemic agent. Because this may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients (excipients) in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Strong CYP3A4/5 inhibitors: When coadministered with strong CYP3A4/5 inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin), the maximum recommended daily dose of saxagliptin is 2.5mg. In these patients, limit the dose of this medicine to 2.5/1000mg once daily. Concomitant administration with insulin: When this medicine is administered with insulin, a lower insulin dose may be required to minimize the risk of hypoglycemia.

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. When used in combination with a diet plan and exercise regimen, Saxagliptin and Metformin together are effective for blood sugar management. This helps stabilize blood sugar levels and aids in diabetes treatment.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients who are not currently being treated with metformin and require saxagliptin 5mg, the recommended starting dose of this medicine is one saxagliptin 5mg/metformin 500mg extended-release tablet once daily; adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. - For patients being treated with metformin, the recommended dose of saxagliptin is 5mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. - For patients switching from combination therapy with saxagliptin and metformin to this medicine, the dose of this medicine may be started at the doses of saxagliptin and metformin previously administered. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. - Patients who require saxagliptin 2.5mg in combination with extended-release metformin may take this medicine at 2.5mg/1000mg. Patients who require saxagliptin 2.5mg but are not being treated with metformin, or who require more than 1000mg of metformin, should take the individual component formulations. The maximum recommended daily dose is saxagliptin 5mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another antihyperglycemic agent. Because this may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients (excipients) in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Strong CYP3A4/5 inhibitors: When coadministered with strong CYP3A4/5 inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin), the maximum recommended daily dose of saxagliptin is 2.5mg. In these patients, limit the dose of this medicine to 2.5/1000mg once daily. Concomitant administration with insulin: When this medicine is administered with insulin, a lower insulin dose may be required to minimize the risk of hypoglycemia.

Precautions

This medication can cause a very rare but potentially fatal metabolic complication called lactic acidosis, so caution is necessary. Patients with moderate to severe renal impairment, cardiovascular disease, acute infections, or severe trauma should not use this medication. It should not be administered to patients with allergic reactions to this drug or those with metabolic acidosis such as lactic acidosis or diabetic ketoacidosis. Before and after tests involving radiologic contrast agents, the administration of this medication should be temporarily suspended and should only be resumed after renal function is confirmed to be normal. It is also safer not to use this medication for pregnant or nursing women and patients with compromised liver function. During treatment with this medication, hypoglycemic symptoms may occur, so it is important to monitor blood sugar levels closely, especially when used together with hypoglycemic agents such as insulin or sulfonylureas. Additionally, this medication can lower vitamin B12 levels, so regular monitoring of vitamin B12 levels is recommended during prolonged use. Caution is required as excessive alcohol consumption or conditions like dehydration, vomiting, or diarrhea can increase the risk of side effects. If sudden symptoms of heart failure or cardiovascular abnormalities occur during treatment with this medication, immediate consultation with a healthcare professional is necessary. If any unusual reactions occur, such as blistering skin conditions or severe joint pain, the use of this medication should be discontinued, and consultation with a specialist is advised. Elderly patients may experience reduced kidney function and should have regular kidney function tests and dosage adjustments made. In cases of overdose, appropriate treatment should be sought immediately at a hospital, and if necessary, the drug can be removed via dialysis. Lastly, keep this medication out of the reach of children, and store it in its original container to prevent degradation of quality.

Side effects

Lactic acidosis, cardiovascular collapse, acute myocardial infarction, sepsis, hypersensitivity reactions, anaphylaxis, angioedema, hypoglycemia, diarrhea, nausea, vomiting, lymphocytopenia, rash, increased blood creatinine, increased serum creatine phosphokinase, upper respiratory tract infections, urinary tract infections, headache, sinusitis, abdominal pain, gastroenteritis, fracture, thrombocytopenia, urticaria, facial edema, tuberculosis, Salmonella sepsis, anorexia, constipation, dyspepsia, hyperglycemia, vitamin D deficiency, hypocholesterolemia, neuropathy, dizziness, vertigo, chest pain, ineffective medication, asthenia, skeletal pain, arthritis, arthropathy, back pain, frequent urination, cystitis, cold, emphysema, lung disease, dyspnea, increased SGPT, increased SGOT, genital pruritus, uterine bleeding, conjunctivitis, cataract, hypertension, heart failure, pruritus, onychocryptosis, hallucinations, cerebral arterial thrombosis, anorexia, constipation, dyspepsia, hyperglycemia, neuropathy, ineffective medication, asthenia, skeletal pain, arthritis, arthropathy, back pain, frequent urination, cystitis, cold, emphysema, lung disease, dyspnea, increased SGPT, increased SGOT, genital pruritus, uterine bleeding, conjunctivitis, cataract, hypertension, heart failure, pruritus, onychocryptosis, hallucinations, cerebral arterial thrombosis, urticaria, facial edema, bullous pemphigoid, acute pancreatitis, arthralgia with severe and disabling symptoms

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale brown and brown, double convex, film-coated tablet

Package unit

28 tablets (7 tablets × 4)/box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.